Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043379 · ClinicalTrials.gov registry record · NA
Post-bypass Prophylactic IVIG in Infants and Neonates
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT02043379 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 50 participants.
The verdict
NCT02043379, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study protocol is to determine if administering Intravenous Immunoglobulin (IVIG) for treatment of cardiopulmonary bypass (CPB) induced hypogammaglobulinemia in the early post-operative period can impact post-surgical outcomes (i.e., infection, fluid overload, and associated morbidities).
Interventions
- OTHER Placebo
- DRUG IVIG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043379
The ClinicalTrials.gov registry entry for NCT02043379 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02043379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043379 about?
NCT02043379 is a clinical study titled "Post-bypass Prophylactic IVIG in Infants and Neonates". The purpose of this study protocol is to determine if administering Intravenous Immunoglobulin (IVIG) for treatment of cardiopulmonary bypass (CPB) induced hypogammaglobulinemia in the early post-operative period can impact post-surgical outcomes (i.e., infection, fluid overload, and associated morb...
What is the current status of trial NCT02043379?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2014-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02043379?
The interventions under investigation include: Placebo (OTHER), IVIG (DRUG).
Who is sponsoring clinical trial NCT02043379?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.